Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 4/20 | 0.45 |
| ▸ | JAK3 | P52333 | 4/20 | 0.45 |
| ▸ | JAK2 | O60674 | 3/20 | 0.45 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | USP2 | O75604 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21495029 | 0.86 | MAPT (0.59) | MAPTKDM4ESMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL21484812 | 0.83 | KMT2A (0.63) | MAPTKDM4ESMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL21484645 | 0.78 | ABL1 (0.57) | MAPTKDM4ESMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL28519673 | 0.78 | LMNA (0.44) | MAPTKDM4ESMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL21484634 | 0.75 | MRE11 (0.58) | MAPTKDM4ESMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL21484682 | 0.74 | ALDH1A1 (0.64) | MAPTKDM4ESMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL21484761 | 0.74 | ABL1 (0.57) | MAPTKDM4ESMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL21484713 | 0.73 | ABL1 (0.68) | MAPTKDM4ESMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL21495017 | 0.71 | AR (0.50) | MAPTSMN1; SMN2KMT2ARAB9AMEN1 | |
| SCHEMBL21484850 | 0.71 | ABL1 (0.69) | MAPTKDM4ESMN1; SMN2KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584742-B2 | Substituted aminothiazoles as inhibitors of nucleases | MASARYKOVA UNIVERZITA (CZ) | 2023-02-21 | — | — | US | disclosed |
| US-20220002282-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2022-01-06 | — | — | US | disclosed |
| CN-112313229-A | Substituted aminothiazoles as inhibitors of nucleases | 马萨里克大学 | 2021-02-02 | — | — | CN | disclosed |
| WO-2019201865-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2019-10-24 | — | — | WO | disclosed |
| WO-2019201865-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2019-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584742-B2 | Substituted aminothiazoles as inhibitors of nucleases | RNASEH1, DNASE1, FEN1 | MAPT 706/4885KDM4E 1848/4885SMN1; SMN2 104/4885 |
| US-20220002282-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | RNASEH1, DNASE1, FEN1 | MAPT 706/4885KDM4E 1848/4885SMN1; SMN2 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.